par LEVY, Antonin;HENDRIKS, Lizza;Berghmans, Thierry 
;Faivre-Finn, Corinne;Giaj-Levra, Matteo;Giaj-Levra, Niccolò;Hasan, Baktiar;Pochesci, Alessia;Girard, Nicolas;Greillier, Laurent;Lantuejoul, Sylvie;Edwards, Christopher John;Brien, Mary O‘;Reck, Martin;Besse, Benjamin;Novello, Silvia;Dingemans, Anne-Marie C;European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group,
Référence European journal of cancer, 122, page (109-114)
Publication Publié, 2019-10-01
;Faivre-Finn, Corinne;Giaj-Levra, Matteo;Giaj-Levra, Niccolò;Hasan, Baktiar;Pochesci, Alessia;Girard, Nicolas;Greillier, Laurent;Lantuejoul, Sylvie;Edwards, Christopher John;Brien, Mary O‘;Reck, Martin;Besse, Benjamin;Novello, Silvia;Dingemans, Anne-Marie C;European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group, Référence European journal of cancer, 122, page (109-114)
Publication Publié, 2019-10-01
Article révisé par les pairs
| Résumé : | Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in non-small-cell lung cancer (NSCLC). A consensus group was formed aiming to agree on a common OM-d that could be used in future clinical trials. A European survey was circulated to generate questions and input for the consensus group meeting. |
